The Clinical Effect of Triglyceride Glucose Index, an Insulin Resistance Marker, in Predicting Neuropathy Induced by the FOLFOX Chemotherapy Protocol

Objective: FOLFOX chemotherapy protocol is a chemotherapeutic agent used in both adjuvant and neoadjuvant of many malignancies such as colon, rectum, stomach, gallbladder, pancreatic cancer. Despite its therapeutic efficacy, neuropathy the most dose-limiting factor. The treatment has not been determined yet. Many clinical studies are ongoing for prevention neuropathy. In our study, we aimed to examine relationship between insulin resistance neuropathic pain due protocol.
 Materials Methods: triglyceride glucose index (TyG-I) before first chemotherapy, at 3rd 6th months patients who developed within 6 did develop underwent diagnosis cancer, was calculated. Neuropathy score calculated using validated test, DN4 questionnaire. questionnaire, it evaluated over 4 points. difference those evaluated. effect TyG-I, an marker, on examined.
 Discussion Conclusion: no found chemotherapy-induced TyG protocol. Additional risk factors pathophysiology oxaliplatin-induced limited literature. Studies literature have diabetes. affecting development still continue be subject research.